BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 28860210)

  • 1. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
    Tawara I; Kageyama S; Miyahara Y; Fujiwara H; Nishida T; Akatsuka Y; Ikeda H; Tanimoto K; Terakura S; Murata M; Inaguma Y; Masuya M; Inoue N; Kidokoro T; Okamoto S; Tomura D; Chono H; Nukaya I; Mineno J; Naoe T; Emi N; Yasukawa M; Katayama N; Shiku H
    Blood; 2017 Nov; 130(18):1985-1994. PubMed ID: 28860210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
    Stauss HJ; Thomas S; Cesco-Gaspere M; Hart DP; Xue SA; Holler A; King J; Wright G; Perro M; Pospori C; Morris E
    Blood Cells Mol Dis; 2008; 40(1):113-6. PubMed ID: 17855129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
    Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
    Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
    Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
    Xue SA; Gao L; Hart D; Gillmore R; Qasim W; Thrasher A; Apperley J; Engels B; Uckert W; Morris E; Stauss H
    Blood; 2005 Nov; 106(9):3062-7. PubMed ID: 16020516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
    Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
    Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytotoxicity of T cells transduced with WT1 peptide-specific T-cell receptor gene against human lung cancer cells in vitro].
    An J; Cai SW; Li Y; Zhang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Aug; 34(9):1319-23. PubMed ID: 25263367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
    Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
    Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
    van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
    Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
    Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
    Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
    Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer.
    Kageyama S; Ikeda H; Miyahara Y; Imai N; Ishihara M; Saito K; Sugino S; Ueda S; Ishikawa T; Kokura S; Naota H; Ohishi K; Shiraishi T; Inoue N; Tanabe M; Kidokoro T; Yoshioka H; Tomura D; Nukaya I; Mineno J; Takesako K; Katayama N; Shiku H
    Clin Cancer Res; 2015 May; 21(10):2268-77. PubMed ID: 25855804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.
    Pan L; Zhang XJ; Niu ZY; Suo XH; Zhang JY; Yang L; Liu XJ; Qiao SK; Dong ZR; Ohno R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):501-7. PubMed ID: 16800930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
    Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
    J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
    Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Wilms' tumor-1 gene expression in myelodysplastic syndrome and its changes in the process of myelodysplastic syndrome transforming into acute leukemia].
    Yang JK; Li JL; Li ZG; Li ZG; Liu PJ; Li JY; Lü HR; Deng Q; Lin XM; Cao JN
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Sep; 15(9):557-9. PubMed ID: 12971856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
    Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
    Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.